I have a story from New Zealand and another one from Spain.
Rats walk again
A June 28, 2025 news item on ScienceDaily announces spinal cord research from New Zealand,
Spinal cord injuries are currently incurable with devastating effects on people’s lives, but now a trial at Waipapa Taumata Rau, University of Auckland offers hope for an effective treatment.
Spinal cord injuries shatter the signal between the brain and body, often resulting in a loss of function.”Unlike a cut on the skin, which typically heals on its own, the spinal cord does not regenerate effectively, making these injuries devastating and currently incurable,” says lead researcher Dr Bruce Harland, a senior research fellow in the School of Pharmacy at Waipapa Taumata Rau, University of Auckland.
Before birth, and to a lesser extent afterwards, naturally occurring electric fields play a vital role in early nervous system development, encouraging and guiding the growth of nerve tissue along the spinal cord. Scientists are now harnessing this same electrical guidance system in the lab.An implantable electronic device has restored movement following spinal cord injury in an animal study, raising hopes for an effective treatment for humans and even their pets.
…
A June 27, 2025 University of Auckland press release, which originated the news item, describes the implantable device in more detail, Note: A link has been removed,
“We developed an ultra-thin implant designed to sit directly on the spinal cord, precisely positioned over the injury site in rats,” Dr Harland says.
The device delivers a carefully controlled electrical current across the injury site.
“The aim is to stimulate healing so people can recover functions lost through spinal-cord injury,” Professor Darren Svirskis, director of the CatWalk Cure Programme at the University’s School of Pharmacy says.
Unlike humans, rats have a greater capacity for spontaneous recovery after spinal cord injury, which allowed researchers to compare natural healing with healing supported by electrical stimulation.
After four weeks, animals that received daily electric field treatment showed improved movement compared with those who did not.
Throughout the 12-week study, they responded more quickly to gentle touch.
“This indicates that the treatment supported recovery of both movement and sensation,” Harland says.“Just as importantly, our analysis confirmed that the treatment did not cause inflammation or other damage to the spinal cord, demonstrating that it was not only effective but also safe.”
This new study, published in a leading journal, has come out of a partnership between the University of Auckland and Chalmers University of Technology in Sweden. See Nature Communications.
“Long term, the goal is to transform this technology into a medical device that could benefit people living with these life-changing spinal-cord injuries,” says Professor Maria Asplund of Chalmers University of Technology.
“This study offers an exciting proof of concept showing that electric field treatment can support recovery after spinal cord injury,” says doctoral student Lukas Matter, also from Chalmers University.
The next step is to explore how different doses, including the strength, frequency, and duration of the treatment, affect recovery, to discover the most effective recipe for spinal-cord repair.
This approach is quite different to that used by the Israeli team featured in my August 22, 2025 posting “Walking again? Israeli team gears up to implant bioengineered spinal cord tissue into paralyzed patient.” It would also appear that at least a few years will pass before the team in New Zealand is ready for human clinical trials.
Here’s a link to and a citation to the New Zealand team’s paper,
Daily electric field treatment improves functional outcomes after thoracic contusion spinal cord injury in rats by Bruce Harland, Lukas Matter, Salvador Lopez, Barbara Fackelmeier, Brittany Hazelgrove, Svenja Meissner, Simon O’Carroll, Brad Raos, Maria Asplund & Darren Svirskis. Nature Communications volume 16, Article number: 5372 (2025) DOI: https://doi.org/10.1038/s41467-025-60332-0 Published: 26 June 2025
Thia paper is open access.
Improving tolerance for prosthetic implants
A June 30, 2025 Universitat Autonoma de Barcelona press release (also on EurekAert) announces development of a new coating for prosthetic devices,
An international research team, including scientists from the Institut de Neurociències at the Universitat Autònoma de Barcelona (UAB), has developed a new solution to reduce the immune response triggered by neural prosthetics used after limb amputations or severe nerve injuries. The approach consists of coating the electronic implants (which connect the prosthetic device to the patient’s nervous system) with a potent anti-inflammatory drug. This coating helps the body better tolerate the implant, improving its long-term performance and stability.
Neural electrode implants are commonly used in prosthetics to restore communication between the device and the nervous system. However, their long-term effectiveness can be compromised by the body’s natural immune reaction to foreign objects, which leads to the formation of scar tissue around the implant and can impair its function.
Now, a recent study published in Advanced Healthcare Materials by researchers from the Universitat Autònoma de Barcelona, the Università di Ferrara, the University of Freiburg, and Chalmers University of Technology, conducted as part of the European collaborative project BioFINE, reports a novel method to improve the biocompatibility and chronic stability of these electrodes.
The technique involves activating and modifying the surface of polyimide (a material commonly used for implanted electrodes) using a chemical strategy that enables the covalent binding of the anti-inflammatory drug dexamethasone. This innovation allows the drug to be released at the implant site slowly over at least two months, a critical period when the immune system typically mounts its strongest response.
Biological tests showed that this approach reduces inflammation-related signals in immune cells, while maintaining the material’s biocompatibility and mechanical integrity. Animal testing further confirmed that the dexamethasone-releasing implants significantly reduce immune reactions and scar tissue formation around the device.
These findings suggest that the slow and localized release of dexamethasone from the implant surface could extend the functional lifespan of neural prostheses, offering a promising step forward in addressing the long-term challenges of implantable neurotechnology.
“This is a main step that has to be complemented by the demonstration in vivo that this coating improves the functional performance of chronically implanted electrodes in the peripheral nerves, for stimulating and recording nerve signals”, says Dr. Xavier Navarro, principal investigator of the UAB team in the BioFINE project.
Here’s a link to and a citation for the paper,
Covalent Binding of Dexamethasone to Polyimide Improves Biocompatibility of Neural Implantable Devices by Giulia Turrin, Jose Crugeiras, Chiara Bisquoli, Davide Barboni, Martina Catani, Bruno Rodríguez-Meana, Rita Boaretto, Michele Albicini, Stefano Caramori, Claudio Trapella, Thomas Stieglitz, Yara Baslan, Hanna Karlsson-Fernberg, Fernanda L. Narvaez-Chicaiza, Edoardo Marchini, Alberto Cavazzini, Ruben López-Vales, Maria Asplund, Xavier Navarro, Stefano Carli. Advanced Healthcare Materials Volume 14, Issue 21 August 19, 2025 2405004 First published online: 17 June 2025 OI: https://doi.org/10.1002/adhm.202405004
This paper is open access.

